戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 amplified breast cancer cell lines and other cancers bearing 11q13 amplification inhibited proliferat
2                                              Cancers bearing activated EGFR can be effectively target
3 e established a clinically relevant prostate cancer-bearing AD mouse model to explore this.
4 tient (index patient) with metastatic breast cancer bearing an activating PIK3CA (phosphatidylinosito
5 s a role in the onset of muscle depletion in cancer-bearing animals and in glucocorticoid-induced atr
6 ic options for treating colorectal and other cancers bearing appropriate cation transporters.
7 herapeutic combination in patients with lung cancers bearing driver mutations.
8 ng improved therapies for patients with lung cancers bearing EGFR mutations.
9 the paraneoplastic complications observed in cancer-bearing flies, suggesting potential therapeutic t
10               Their ability to differentiate cancer-bearing from non-cancer-bearing tissues was evalu
11  reproduced in animal models of TRL-positive cancer bearing G-CSF expressing cervical cancer cells.
12  therapy that involves administration to the cancer-bearing host of immune cells with direct anticanc
13 d-derived suppressor cells (MDSCs) expand in cancer-bearing hosts and contribute to tumor immune evas
14  The immunologic basis of NK-cell defects in cancer-bearing hosts has not been extensively studied.
15 lectively take up angiogenesis regulators in cancer-bearing hosts may have implications for the diagn
16     Neutrophils are expanded and abundant in cancer-bearing hosts.
17 as led to encouraging therapeutic results in cancer-bearing hosts.
18 active T cells would inhibit tumor growth in cancer-bearing hosts.
19 le in the aberrant hematopoiesis observed in cancer-bearing hosts.
20 y between and within tumors as well as among cancer-bearing individuals, and all of these factors tog
21  treatment of the 30% of sporadic human lung cancers bearing LKB1 mutations.
22  targeting specifically VEGF-A, and in colon cancer-bearing mice (CT26) treated with drugs targeting
23  LNneg is associated with better survival in cancer-bearing mice and might explain increased LN size.
24 cells found in ascites of epithelial ovarian cancer-bearing mice at advanced stages of disease are im
25 ic angiogenesis induced by cav-1 in prostate cancer-bearing mice correlated with an increased frequen
26 d cisplatin improved the survival of ovarian cancer-bearing mice in an orthotopic model.
27 n a two-phase solution system and in vivo in cancer-bearing mice indicates that the process of drug d
28  therapy regimen for the treatment of breast cancer-bearing mice prolonged the vaccine-induced progre
29                          CLEC-2 depletion in cancer-bearing mice resulted in not only reduced cancer-
30 D11b(+)Gr-1(+) cells from ascites of ovarian cancer-bearing mice results in the significant regressio
31 imed CD4(+) T cells transferred into ovarian cancer-bearing mice secrete high levels of CCL5, which r
32                                              Cancer-bearing mice that expressed KLF2 converted tumor-
33                        Additionally, ovarian cancer-bearing mice treated with ITLN1 demonstrate marke
34 aluated in orthotopic triple-negative breast cancer-bearing mice treated with palbociclib to induce s
35 n as ferroptosis in starved cancer cells and cancer-bearing mice.
36 ficacy of alphaPD-L1 in immunocompetent lung cancer-bearing mice.
37 ated > 5000 candidates in each of the breast cancer-bearing mice.
38 graphy (microCT) images acquired from breast cancer-bearing mice.
39 ografts and prolongs the survival of ovarian cancer-bearing mice.
40 uring the formation of metastatic lesions in cancer-bearing mice.
41                            The study of both cancer-bearing mouse models in wild types and their corr
42                      Unexpectedly, RER colon cancers bearing mutant p53 demonstrated the same stabili
43 reduced liver metastases in human pancreatic cancer-bearing nude mice.
44 heir utility to date is primarily limited to cancers bearing oncogenic kinase mutations.
45 recision oncology agents that are matched to cancers bearing oncogenically activated versions of thei
46  of p53 is crucial for successful therapy of cancers bearing p53 mutations.
47 pecific pathways perturbed in the T cells of cancer-bearing patients will allow us to assess steps to
48 s with anti-tumour activity can be raised in cancer-bearing patients.
49 long-term physiological impacts in naive and cancer-bearing rats.
50 enotype and outcome among patients with lung cancer bearing similar mutations, suggesting that other
51  BET inhibitors in individuals with prostate cancer bearing SPOP mutations.
52 labeled MSLN HLE BiTE molecule in 4T1 breast cancer bearing syngeneic mice with positron emission tom
53 2-fold increase over normal expression among cancers bearing the corresponding chromosomal amplificat
54           Normal vascular endothelium in non-cancer-bearing tissue was consistently PSMA negative.
55 ity to differentiate cancer-bearing from non-cancer-bearing tissues was evaluated using a machine lea